{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.6","upperLimit":"37.2","value":"26"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"9.5","value":"0"},{"groupId":"OG002","lowerLimit":"58.5","upperLimit":"76.9","value":"68.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"112"}],"units":"Participants"}],"description":"Skin lesion response rate in the double-blind period was determined only among patients with at least one skin lesion at baseline, and is the percentage of this group of patients with a best overall skin lesion response on the Physician's Global Assessment of Clinical Condition (PGA) of either complete clinical response (CCR) or partial response (PR). A complete clinical response (CCR) requires a grading of 0 indicating the absence of disease (histological confirmation is not required). Grades 1, 2, and 3 constitute partial response, indicating improvement of at least 50 percent, but less than 100 percent improvement. For the everolimus (core/extension periods) treatment group, the baseline means the latest value on or before starting everolimus.","dispersionType":"95% Confidence Interval","groups":[{"description":"Study drug was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG000","title":"Everolimus Randomized (Core Period)"},{"description":"Placebo was given by continuous oral daily dosing of two 5 mg tablets.","id":"OG001","title":"Placebo Randomized (Core Period)"},{"description":"Patients initially randomized in everolimus and patients initially randomized in placebo but who crossed-over to everolimus during extension.","id":"OG002","title":"Everolimus (Core and/or Extension Period)"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) is defined according to the Intention-to-Treat principle and consists of all randomized patients. Only patients with at least one skin lesion at baseline are included in the analysis.","reportingStatus":"POSTED","timeFrame":"From date of randomization until the earliest date of first documented AML progression, date of further anti-AML medication (including open-label Everolimus)/surgery or up to 5.7 years","title":"Skin Lesion Response Rate as Per Investigator (Only Patients With at Least One Skin Lesion at Baseline)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}